Analysis of vitamin D availability in patients with irritable bowel syndrome of various etiologies
https://doi.org/10.21886/2712-8156-2025-6-3-77-81
Abstract
Objective: to analyze vitamin D availability in patients with irritable bowel syndrome of various etiologies.
Materials and methods: 148 patients with irritable bowel syndrome with a predominance of diarrhea were examined. Group I included 88 patients with irritable bowel syndrome after COVID-19; group II included 60 patients in whom the disorder was stress–induced. The control group included 30 relatively healthy subjects. Vitamin D availability was assessed for all participants.
Results: an analysis of vitamin D provision in patients suffering from irritable bowel syndrome showed a predominance of patients with reduced levels of this micronutrient. In both groups of patients with irritable bowel syndrome, the incidence of vitamin D deficiency was significantly higher than in the control group. Thus, in group I, a decrease in serum calcidiol levels was found in 63 (71.6 %) patients, which was statistically significantly (p < 0.001) higher than in the control group, and in group II — in 24 (40.0 %) patients (p < 0.01), where the disorder was induced by stress.
Conclusions: patients with irritable bowel syndrome are characterized by an insufficient supply of vitamin D. At the same time, this imbalance is more typical for patients who have developed IBS against the background of a new coronavirus infection.
Supporting agencies: The study had no sponsorship support
About the Authors
P. I. Naletova
Donetsk Central City Clinical Hospital No. 1
Russian Federation
Russian Federation
Polina I. Naletova, infectiologist
Donetsk People Republic; Donetsk
Ja. A. Sockaya
Lugansk State Medical University n. a. St. Luke
Russian Federation
Russian Federation
Jana A. Sockaya, MD, PhD, DSc, Professor, Head of the Department
Department of Infectious Diseases and Epidemiology
Lugansk People Republic; Lugansk
A. V. Nalеtov
M. Gorky Donetsk State Medical University
Russian Federation
Russian Federation
Andrew V. Naletov, MD, PhD, DSc, Professor, Head of the Department
Department of Pediatrics No. 2
Donetsk People Republic; Donetsk
References
1. Dzhulay G.S., Dzhulay T.E. Clinical and pathogenic features of COVID-19- associated diarrhea syndrome. Experimental and Clinical Gastroenterology. 2022;(9):276-283. (In Russ.) doi: 10.31146/1682-8658-ecg-205-9-276-283
2. Nalyotov A. V., Shapchenko T. I., Guz N. P. Some clinical and pathogenetic aspects of irritable bowel syndrome in patients who have undergone COVID-19. Experimental and Clinical Gastroenterology. 2023;(7):60-65. (In Russ.) doi: 10.31146/1682-8658-ecg-215-7-60-65
3. Boraeva T.T., Ataeva M.V., Hirihanova A.A., Tatrova V.M., Mucol’gov B.A. The frequency of cardiovascular pathology and the consequences of SARS-COV-2 virus infection in children of the Republic of North Ossetia-Alania. Medicine. Sociology. Philosophy. Applied research. 2023; 6: 151-154. (In Russ.) eLIBRARY ID: 59557440 EDN: XOLYMG
4. Novikova V.P., Polunina A.V., Bannova S.L., Balashov A.L., Dudurich V.V., Danilov L.G. et al. Gastrointestinal tract in children with novel coronavirus infection and post-COVID-19 syndrome. The role of synbiotics for improving clinical symptoms, gut microbiota, and intestinal permeability. Russian Journal of Woman and Child Health. 2023; 6 (3): 283-289 (in Russ.). doi: 10.32364/2618-8430-2023-6-3-10
5. Naletov A.V., Masjuta D.I., Chalaja L.F. Pathogenetic basis of irritable bowel syndrome in patients who have undergone COVID-19. Mother and Child in Kuzbass. 2021;(4):12-16. (In Russ.) doi: 10.24412/2686-7338-2021-4-12-16
6. Marasco G, Maida M, Cremon C, Barbaro MR, Stanghellini V, Barbara G. Meta-analysis: Post-COVID-19 functional dyspepsia and irritable bowel syndrome. Aliment Pharmacol Ther. 2023;58(1):6-15. doi: 10.1111/apt.17513
7. Grinevich V.B., Lazebnik L.B., Kravchuk Yu.A., Radchenko V.G., Tkachenko E.I., Pershko A.M., et al. Gastrointestinal disorders in post-COVID syndrome. Clinical guidelines. Experimental and Clinical Gastroenterology. 2022;(12):4-68. (In Russ.) doi: 10.31146/1682-8658-ecg-208-12-4-68
8. Settanni CR, Ianiro G, Ponziani FR, Bibbò S, Segal JP, Cammarota G, et al. COVID-19 as a trigger of irritable bowel syndrome : A review of potential mechanisms. World J Gastroenterol. 2021;27(43):7433-7445. doi: 10.3748/wjg.v27.i43.7433
9. Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk factors, and management. BMJ. 2021;374:n1648. Erratum in: BMJ. 2021;374:n1944. doi: 10.1136/bmj.n1648
10. Contreras-Bolívar V., García-Fontana B., García-Fontana C. Muñoz-Torres M. Vitamin D and COVID-19: where are we now? Postgrad Med. 2023; 135 (3): 195-207. doi: 10.1080/00325481.2021.2017647
11. Ivashkin V.T., Maev I.V., Shelygin Yu.A., Baranskaya E.K., Belous S.S., Belousova E.A., et al. Diagnosis and Treatment of Irritable Bowel Syndrome: Clinical Recommendations of the Russian Gastroenterological Association and Association of Coloproctologists of Russia. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(5):74-95. (In Russ.) doi: 10.22416/1382-4376-2021-31-5-74-95
Review
For citations:
Naletova P.I., Sockaya J.A., Nalеtov A.V. Analysis of vitamin D availability in patients with irritable bowel syndrome of various etiologies. South Russian Journal of Therapeutic Practice. 2025;6(3):77-81. (In Russ.) https://doi.org/10.21886/2712-8156-2025-6-3-77-81
Views:
47
Email this article 